A downtrend has been apparent in Aptevo Therapeutics Inc. (APVO) lately. While the stock has lost 12% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish ca ...

Core Insights - Aptevo Therapeutics has presented preclinical data for its trispecific antibody candidate, APVO451, at the Society for Immunotherapy of Cancer Annual Meeting, highlighting its potential in treating hard-to-treat solid tumors [1][2]. Company Update - APVO451 is designed to address the challenge of immune suppression in solid tumors, such as urothelial, breast, and pancreatic cancers, by utilizing a proprietary CRIS-7-derived CD3 binding domain [2][3]. - The molecule aims to activate the intratumoral immune system, enhancing the ability to target and kill tumor cells effectively [3]. Key Findings from the Presentation - APVO451 demonstrated local activation of T-cells and antigen-presenting cells (APCs) only when bound to the target protein, nectin-4, indicating a favorable safety profile [4]. - The candidate showed dual immune re-activation by stimulating T-cell effector functions and restoring APC function, addressing a common failure point in solid tumor treatments [4]. - In tumor models simulating suppression, APVO451 was more effective in eliminating nectin-4-positive tumor cells compared to standard CD3 T-cell engagers, suggesting its potential to overcome suppressive tumor environments [4]. Next Steps - Aptevo is advancing APVO451 through ongoing preclinical studies to support IND-enabling work and future clinical development targeting nectin-4-expressing solid tumors [5]. About APVO451 - APVO451 is a trispecific ADAPTIR-FLEX therapeutic candidate designed to engage CD3 and CD40, aiming to restore immune engagement in suppressive solid tumors while minimizing off-tumor activation [6]. About Aptevo Therapeutics - Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment, with two clinical candidates currently in trials [7].

Clinical Development - Mipletamig reported an 89% remission rate among evaluable frontline AML patients, with 100% remission in Cohort 3 of the ongoing RAINIER trial[99]. - No cytokine release syndrome (CRS) observed among evaluable frontline patients to date, distinguishing it from other treatments[99]. - The ongoing Phase 1b trial for mipletamig was initiated in August 2024, with favorable results reported to date[91]. - The company has two clinical candidates and six preclinical candidates currently in development, focusing on novel immunotherapy for cancer treatment[91]. - The company has an obligation to make a $2.0 million milestone payment upon dosing the first patient in a Phase 2 clinical trial of mipletamig under the OMT License Agreement[124]. Financial Performance - Research and development expenses increased by $0.9 million to $4.0 million for the three months ended September 30, 2025, compared to $3.1 million for the same period in 2024[102]. - General and administrative expenses rose by $1.5 million to $3.6 million for the three months ended September 30, 2025, compared to $2.1 million for the same period in 2024[104]. - Net cash provided by financing activities was $32.7 million for the nine months ended September 30, 2025, compared to $8.9 million for the same period in 2024[109]. - Total research and development expenses for the nine months ended September 30, 2025, were $11.0 million, up from $10.5 million in the same period in 2024[102]. - For the nine months ended September 30, 2025, net cash used in operating activities was $20.4 million, indicating ongoing operational losses[117]. - The company anticipates significant operating losses for the next several years as it continues to develop its product candidates, requiring substantial additional funding[117]. Capital Raising and Agreements - The company raised $18.7 million net in the third quarter, extending cash runway into Q4 2026[99]. - The company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, allowing the issuance of up to $25 million in common stock over 36 months, with $15 million raised from 8.3 million shares issued as of September 30, 2025[110]. - Under the At The Market Offering Agreement (ATM Agreement), the company raised $7.6 million from the issuance of 2.8 million shares at an average price of $2.74 per share for the nine months ended September 30, 2025[111]. - The company has no remaining availability under the ATM Agreement due to limitations, but has $10 million remaining under the SEPA[111][118]. - The company has 12,535,033 common warrants outstanding, which could yield up to $23.9 million in gross proceeds if exercised[115]. - The company received $9.6 million from XOMA for the sale of future deferred payments and potential milestones related to IXINITY, with an additional $5.8 million in milestone payments contingent on regulatory achievements[114]. Market and Operational Challenges - The company may face delays in clinical trials and partnerships due to macroeconomic factors, including inflation and potential impacts on partners' financial stability[120]. - The company has cash and cash equivalents of $21.1 million and an accumulated deficit of $269.2 million as of September 30, 2025[116].

Clinical Trials and Product Development - 89% of evaluable frontline AML patients achieved remission with mipletamig in combination therapy across two trials, including 100% remission in Cohort 3 of the RAINIER trial[3] - Aptevo introduced its first trispecific T-cell engagers, APVO451 and APVO452, expanding its oncology portfolio to five CRIS-7-derived CD3-targeting molecules[4] - Aptevo's pipeline now includes six preclinical candidates targeting various solid tumors, leveraging its proprietary ADAPTIR and ADAPTIR-FLEX platforms[18] Financial Performance - The company raised $18.7 million in Q3 2025 and an additional $4.1 million post-quarter, extending its cash runway into Q4 2026[10] - Cash and cash equivalents totaled $21.1 million as of September 30, 2025, increasing to $25.2 million after additional fundraising[10] - Research and development expenses rose to $4.0 million in Q3 2025, up from $3.1 million in Q3 2024, primarily due to increased mipletamig and employee costs[11] - General and administrative expenses increased to $3.6 million in Q3 2025, compared to $2.1 million in Q3 2024, mainly due to higher employee costs[12] - Aptevo reported a net loss of $7.5 million or $2.23 per share for Q3 2025, compared to a net loss of $5.1 million or $357.86 per share in Q3 2024[12] - The total assets of Aptevo increased to $26.996 million as of September 30, 2025, from $15.591 million at the end of 2024[15] - The company’s accumulated deficit reached $269.2 million as of September 30, 2025, compared to $247.6 million at the end of 2024[15] Risks and Uncertainties - Aptevo's actual results may differ materially from forward-looking statements due to various risks, including clinical trial uncertainties and regulatory changes[21] - The company faces known and unknown risks that could impact the availability or commercial potential of its product candidates[21] - Macroeconomic conditions such as rising inflation, interest rates, and decreased consumer confidence are potential factors affecting Aptevo's performance[21] - The ongoing geopolitical risks, including the war between Russia and Ukraine, may also influence the company's business environment[21] - Aptevo does not assume any obligation to update forward-looking statements unless required by law[21]

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1] Summary by Categories Technical Requirements - Users are advised to enable Javascript and cookies in their browsers to ensure proper functionality [1] - The presence of ad-blockers can lead to blocked access, necessitating their temporary disablement [1]

Core Insights - Aptevo Therapeutics reported that 89% of evaluable frontline AML patients achieved remission in combination therapy across two trials, with a notable 100% remission rate in Cohort 3 of the ongoing RAINIER trial [1][1][1] - The company introduced its first trispecific molecules, APVO451 and APVO452, aimed at overcoming immune suppression in certain solid tumors, utilizing a unique CRIS-7-derived CD3 binding domain [1][1][1] - Aptevo's CD3 T-cell engager portfolio has been expanded to five molecules, indicating growth in its therapeutic offerings [1][1][1] - The company raised $18.7 million in the third quarter and an additional $4.1 million since the quarter ended, extending its cash runway into the fourth quarter of 2026 [1][1][1] Financial Performance - The financial results for the quarter ended September 30, 2025, were reported alongside a business update, highlighting the company's ongoing development in immune-oncology therapeutics [1][1][1]

Core Insights - Aptevo Therapeutics is actively participating in several key financial, industry, scientific, and medical conferences this fall to showcase its ongoing developments and momentum in the biotechnology sector [1] Conference Participation - Aptevo will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, discussing its lead asset mipletamig and its clinical progress in Acute Myeloid Leukemia (AML) [1] - The company will also be present at the Biotechnology Innovation Organization (BIO)-Europe 2025 from November 3-5, 2025, engaging in meetings at the largest biotechnology event in Europe [1] - At the Society of Immunotherapy in Cancer (SITC) 2025, scheduled for November 5-9, 2025, Aptevo's R&D team will present a poster on a novel trispecific targeting approach to address the immunosuppressive tumor microenvironment [1] - The interim results from the ongoing Phase 1b/2 RAINIER trial evaluating mipletamig in frontline combination therapy for AML will be presented at the American Society of Hematology (ASH) 2025 meeting from December 6-9, 2025 [1]

Group 1: Telomir Pharmaceuticals Inc - Telomir Pharmaceuticals Inc's shares rose 31% to $1.86 in pre-market trading following the release of promising preclinical study results for its lead compound, Telomir-1 [1] - The preclinical study indicated that Telomir-1 was able to reverse abnormal DNA methylation in aggressive prostate cancer models [1] Group 2: Other Stocks in Pre-Market Trading - Spruce Biosciences Inc gained 90.9% to $248.89, while C3is Inc surged 73.3% to $3.83 in pre-market trading [5] - Aptevo Therapeutics Inc increased by 40.2% to $1.98, and Galecto Inc rose 37.5% to $5.10 [5] - Datavault AI Inc surged 27.8% to $2.66, reaffirming its 2H 2025 revenue guidance of $12 million to $15 million [5] - Processa Pharmaceuticals Inc gained 27.5% to $0.36, and BTQ Technologies Corp rose 25.7% to $11.44 [5] - DBV Technologies SA gained 12.8% to $14.99 after announcing the sale of approximately $30 million of ADSs [5] - Amkor Technology Inc jumped 11.2% to $33.99, announcing an expanded investment in semiconductor packaging and testing in Arizona [5] Group 3: Declining Stocks - Society Pass Inc shares dipped 24.6% to $4.00 after a significant jump of 276% on Monday [5] - Dermata Therapeutics Inc fell 19.1% to $4.35, and Aether Holdings Inc declined 16.8% to $4.51 [5] - SANUWAVE Health Inc dipped 14.4% to $34.99, cutting its FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [5] - Lazydays Holdings Inc fell 12.3% to $2.57, while NOVONIX Ltd tumbled 12.3% to $1.57 [5] - OneMedNet Corp dipped 12.1% to $2.25 after a significant jump of 149% on Monday [5]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 150 points, closing up 0.37% at 46,190.85, NASDAQ rising 1.07% to 22,500.28, and S&P 500 gaining 0.62% to 6,641.29 [1] - In the commodities market, oil prices rose by 0.7% to $64.50, while gold decreased by 1.2% to $3,674.30 [5] Company Performance - Darden Restaurants, Inc. reported first-quarter earnings of $1.97 per share, missing the analyst consensus estimate of $2.00 per share, and quarterly sales of $3.004 billion, which also fell short of the $3.040 billion estimate [2] - 89bio, Inc. shares surged 86% to $15.02 following an acquisition agreement with Roche [8] - Intel Corporation's shares increased by 27% to $31.59 after announcing a partnership with NVIDIA for AI infrastructure development, with NVIDIA investing $5 billion in Intel's stock at $23.28 per share [8] - Aptevo Therapeutics Inc. saw its shares rise by 62% to $2.2863 due to breakthrough clinical results for its drug in AML treatment [8] - Replimune Group, Inc. shares fell by 39% to $3.4900 as the company assesses FDA feedback on its product [8] - BioCardia, Inc. shares dropped 29% to $1.0850 after announcing a public offering and trial results [8] - Lifeway Foods, Inc. shares decreased by 21% to $26.72 following Danone's withdrawal of its acquisition proposal [8] Economic Indicators - U.S. initial jobless claims decreased by 33,000 to 231,000, better than the market estimate of 240,000 [10] - The Philadelphia Fed Manufacturing Index rose to +23.2 in September, the highest since January, compared to -0.3 in August [10] European and Asian Markets - European shares showed positive movement, with the eurozone's STOXX 600 rising by 0.79% and major indices in Spain, London, Germany, and France also gaining [6] - Asian markets closed mixed, with Japan's Nikkei gaining 1.15% while Hong Kong's Hang Seng fell by 1.35% [7]

Market Overview - U.S. stocks traded mostly higher, with the Nasdaq Composite gaining over 100 points on Thursday [1] - The Dow decreased by 0.04% to 46,000.59, while the NASDAQ rose by 0.49% to 22,370.12 and the S&P 500 increased by 0.29% to 6,619.34 [1] Sector Performance - Information technology shares increased by 0.8% on Thursday [1] - Materials stocks fell by 0.7% [2] Economic Indicators - U.S. initial jobless claims declined by 33,000 to 231,000 in the second week of September, better than market estimates of 240,000 [3][9] - The Philadelphia Fed Manufacturing Index rose to +23.2 in September, the highest level since January, compared to -0.3 in August [11] Commodity Prices - Oil prices increased by 0.5% to $64.37, while gold decreased by 0.4% to $3,701.70 [6] - Silver fell by 0.1% to $42.110 and copper dropped by 0.5% to $4.6135 [6] International Markets - European shares were higher, with the eurozone's STOXX 600 rising by 0.8% [7] - Asian markets closed mixed, with Japan's Nikkei gaining 1.15% and Hong Kong's Hang Seng falling by 1.35% [8] Company News - 89bio, Inc. shares surged 85% to $14.97 after announcing an acquisition agreement with Roche [10] - Aeries Technology, Inc. shares also rose 85% to $1.0500 following a partnership announcement with an annual contract value of up to $8 million [10] - Aptevo Therapeutics Inc. shares increased by 57% to $2.2201 after breakthrough clinical results [10] - Replimune Group, Inc. shares dropped by 40% to $3.4288 as the company evaluates FDA feedback [10] - BioCardia, Inc. shares fell by 34% to $1.02 after announcing a public offering and trial results [10] - Office Properties Income Trust shares decreased by 28% to $0.4066 [10]